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Abstract
Background:  Burning  mouth  syndrome  (BMS)  is  a  frequently 
occurring disease characterized by a burning or painful sensation 
in the tongue and/or other oral sites without clinical mucosal ab-
normalities or lesions. Its etiopathology is unknown, although lo-
cal, systemic, and psychological factors have been associated with 
BMS. The syndrome is multifactorial, and its management remains 
unsatisfactory. The purpose of this study was to obtain preliminary 
data regarding the efficacy and tolerability of amisulpride in BMS 
treatment.
Methods: The subjects were treated with amisulpride (50 mg/day) 
for 24 weeks. Efficacy assessment included a visual analogue scale 
(VAS) for pain intensity, the Hamilton Rating Scale for Depression 
(HAM-D), the Hamilton Rating Scale for Anxiety (HASM-A), and 
the Clinical Global Impression Scale-Efficacy Index (CGI-EI).
Results: The treatment regimens resulted in a significant improve-
ment in burning mouth symptoms from baseline at week 24, as in-
dicated by the quantitative mean illness duration VAS score, HAM-
D, and HAM-A. Amisulpride appears to be effective and patients 
show a rapid response to treatment. No serious adverse effects were 
encountered in these patients.
Conclusions: Amisulpride is effective and well tolerated as a short-
term treatment. It is particularly efficacious at the start of treatment 
and has shorter response latency. Double-blind placebo-controlled 
trials are needed for further assessment of the efficacy of amisul-
pride in BMS treatment.
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Introduction
Primary burning mouth syndrome (BMS) is a chronic, id-
iopathic intraoral mucosal pain condition that is not accom-
panied by clinical lesions or systemic disease. Whether this 
condition should be referred to as a disease, disorder, or 
syndrome is uncertain, but data to justify any change in tax-
onomy are insufficient at present. BMS is often accompanied 
by xerostomia and taste disturbances. A neuropathological 
basis for BMS has recently been proposed, suggesting that it 
could be regarded as an oral dysesthesia or painful neuropa-
thy. However, our incomplete understanding of the epidemi-
ology, etiology, and pathophysiology of BMS, and the lack 
of any diagnostic criteria, are barriers to critical investigation 
and the selection of effective treatments [1]. There is only 
limited evidence to guide clinicians in the management of 
patients with BMS. The estimated prevalence of BMS re-
ported in recent studies ranges between 0.7% and 4.6% of 
the general population; most cases occur in postmenopausal 
women. The rate of occurrence of this disorder in women 
is 20% higher than that in men [2]. The most prevalent co-
morbidity is a major depressive episode. No other psychiat-
ric disorders have been associated with BMS in comparison 
with healthy people [3, 4].
Amisulpride is a selective dopamine antagonist. It has 
a high affinity for D2 (Ki = 2.8 nM) and D3 (Ki = 3.2 nM) 
dopaminergic receptors. Dosage ranges from 200 to 1200 
mg/day. Lower doses (less than 50 mg) preferentially block 
D2 autoreceptors, which control the synthesis and release of 
dopamine. This results in an increase in dopaminergic trans-
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mission, which is hypothesized to cause a reduction in both 
depressive and negative symptoms. Higher doses of the drug 
block the postsynaptic dopamine receptors, resulting in an 
improvement in symptoms of psychosis. It is an atypical an-
tipsychotic drug and has a low incidence of extrapyramidal 
side effects [5].
Although substantial evidence indicates the efficacy of 
some antidepressants in treating psychogenic pain and so-
matoform disorders, very few studies have investigated their 
possible therapeutic action in cases of BMS. The aim of this 
study was to demonstrate the efficacy and tolerability of ami-
sulpride in a group of patients with BMS.
Materials and Methods
Patients for this study were recruited at the net of the hos-
pitals of the National Galician Health Service in the North-
western  of  Spain.  Twenty-four  subjects  with  BMS  were 
screened consecutively for inclusion in this study, but only 
22 patients, all female, gave their written consent and par-
ticipated. All patients met the DSM-IV (Diagnostic and Sta-
Table 1. Patient’s Characteristics
Gender (female) Age
Age at 
onset
Illness duration at
our first time (months)
Previous 
treatments
Female 56 54 36 Fluoxetine
Female 67 65 34 Paroxetine
Female 65 65 37 Fluoxetine, 
Female 73 72 24 Paroxetine
Female 49 48 34 Paroxetine
Female 67 66 18 Paroxetine
Female 58 57 24 Paroxetine
Female 54 53 27 Sertraline
Female 68 66 33 Sertraline
Female 60 59 18 Paroxetine
Female 71 70 25 Sertraline
Female 58 56 34 Fluoxetine 
Female 64 63 12 Fluoxetine 
Female 71 69 8 Paroxetine
Female 61 61 12 Paroxetine
Female 45 43 14 Paroxetine
Female 54 53 12 Paroxetine
Female 56 53 16 Fluoxetine
Female 65 64 33 Fluoxetine
Female 57 56 24 Fluoxetine
Mean ± SD 60.95 ± 7.57 59.65 ± 7.70 2.75 ± 9.48 FluoxetineJ Clin Med Res  •  page no. to be assigned           Treatment of Burning Mouth Syndrome
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tistical Manual of Mental Disorders, 4th edition) diagnostic 
criteria for BMS.
Depressive symptoms were evaluated according to the 
Hamilton Rating Scale for Depression (HAM-D); anxiety 
symptoms were evaluated using the Hamilton Rating Scale 
for Anxiety (HAM-A); and the clinical efficacy and toler-
ability  of  the  treatment  were  assessed  using  the  Clinical 
Global Impressions scale (CCG). The rating scales were ad-
ministered at baseline and every 2 weeks until week 8 and 
then every 4 weeks until 24 weeks. Diagnostic assessment 
was carried out using the Diagnostic Interview Schedule-
Revised (DIS-R, a highly structured interview that carefully 
specifies the questions that the interviewer must ask to make 
a diagnosis). Patients were excluded if they had a severe ill-
ness, were pregnant or lactating, had a history of breast or 
genitourinary cancer, or had an allergy or intolerance to ami-
sulpride. Patients who met the DSM-IV criteria for psychotic 
disorders or concurrent depression were also excluded from 
the study. None of the patients had taken any psychoactive 
drug for at least 4 weeks before the time of admission, and 
no concomitant psychotropic or psychotherapeutic treatment 
was permitted for the duration of study. Other oral diseases/
disorders were ruled out prior to inclusion in the study.
At  the  time  of  recruitment,  each  patient  was  treated 
with 50 mg of amisulpride. The treatment was continued 
for 6 months at the same dose. Failure to comply with treat-
ment (missing more than 2 consecutive doses of the drug) 
and withdrawal of participant’s consent were the criteria for 
withdrawal from the study.
Clinical assessment
The patients were asked to indicate the mean pain intensity 
during the week preceding the consultation by scoring on a 
vertical 10-cm visual analogue scale (VAS).
Depressive symptoms were evaluated according to the 
HAM-D scale; anxiety symptoms, using HASM-A; and clin-
ical efficacy and tolerability of the treatment, using CGI-EI. 
The rating scales were administered at baseline and every 2 
weeks until week 8 and every 4 weeks until the end of the 
study (24 weeks) by a trained psychologist. 
Statistical procedures
Analysis of variance (ANOVA) was used to test for compa-
rability of treatment by using continuous variables such as 
index age, age onset, and baseline scores for the VAS, HAM-
D, HAM- A, and CGI-Efficacy Index (EI).
Table 2. Rating VAS, HMA-A, HAM-D Scores (mean ± SD) During Treat-
ment With Amisulpride
VAS: Visual Analogue Scale; HAM-A: Hamilton Rate Scale for Anxiety; HAM-D: 
Hamilton Rate Scale for Depression.
Scale VAS HAM-A HAM-D
Baseline 8.35 ± 0.67 21.10 ± 1.91                                                                                                      20.80 ± 1.47
Week 2 7.0 ± 0.56 15.20 ± 1.36 14.05 ± 1.93
Week 4 5.85 ± 0.87 3.15 ± 1.69 10.80 ± 2.41
Week 6 3.35 ± 0.58 7.90 ± 1.07 8.60 ± 0.59
Week 8 1.15 ± 0.93 4.85 ± 1.18 6.80 ± 0.76
Week 12 1.15 ± 0.81 6.65 ± 0.67 4.70 ± 1.12
Week 16 1.15 ± 0.87 6.45 ± 0.51 4.70 ± 1.03
Week 20 1.05 ± 0.88 6.60 ± 0.75 4.80 ± 1.19
Week24 1.05 ± 0.87 6.55 ± 0.68 4.68 ± 0.98J Clin Med Res  •  page no. to be assigned Rodriguez-Cerdeira et al
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A comparative qualitative evaluation of treatment re-
sponse was also performed by calculating the percentage of 
responses in each group. The software used for the analysis 
was the Statistical Package for the Social Sciences (SPSS), 
version 18.0.1) (SPSS Inc, Chicago, IL).
 
Results
Twenty-two patients were recruited and assigned to receive 
amisulpride. One patient was excluded for the lack of com-
pliance and another refused to continue the study because of 
side effects. Ultimately, 20 patients were included. A summa-
ry of demographic information, including gender, index age, 
age at onset of BMS, and illness duration is shown in Table 1.
These variables did not differ significantly with respect 
to the total scores at baseline (VAS, HAM-A, HAM-D, and 
CGI-EI).
The amisulpride treatment regimen resulted in a sig-
nificant improvement in BMS from the baseline at week 6 
(Table 2), as demonstrated by VAS total scores at the end 
of the study. A large improvement was also observed in the 
final HMA-D and HMA-A total scores from baseline to the 
end of week 8 (Table 3). Both the severity of illness (CGI-S) 
and improvement (CGI-EI) scales showed steady improve-
ment over 8 weeks. The mean ± SD CGI-EI scores were 4.2 
± 1.2 at baseline and 2.5 ± 0.9 at week 8 and remained more 
or less constant until week 24. 
VAS, HAM-A, and HAM-D mean scores decreased sig-
nificantly from baseline to week 2 (Table 2), indicating the 
speed of action of amisulpride. These scales also show that 
this improvement increased significantly until week 6. The 
percentage of response at week 8 was 100% (Table 3) and 
remained at this level through week 24. No serious adverse 
effects were reported. However, the most frequently encoun-
tered side effects were as follows: insomnia in 4 patients, 
tremor in 3 patients, headache in 2 patients, nausea/dyspep-
sia and sedation in other patient. The occurrence of these 
side effects is shown in Table 4.
Discussion
  
We carried out a review of the articles and clinical case stud-
ies published in the literature between 2001 and 2011, de-
scribing different pharmacological options for the treatment 
of BMS. To our knowledge, this is the first systematic study 
of amisulpride in the treatment of BMS by using established 
diagnostic criteria and rating scales over a long period. The 
data relating to the efficacy and safety of each of the drugs 
used in the different studies have been reviewed. However, 
the clinical trials conducted to date are not par¬ticularly ro-
bust. Most of them are open-label uncontrolled studies in-
volving small patient groups and short time periods. Further-
more, the expression of results is heterogeneous [6, 7].
Although  effective  therapies  have  been  identified  in 
specific cases, a treatment modality that offers efficacy in 
most cases of BMS has not yet been established. Further in-
Table  3.  Cumulative  Proportion  of  Responders  at 
Weeks 2, 4, 6, 8, 12,16, 20 and 24 During Treatment 
With Amisulpride (NP = 20)
Table 4. Side Effects
NP: Number of the patients.
Number of patients = 20.
Time  Number of patients %
Week 2 6 30
Week 4 8 43
Week 6 17 85
Week 8 20 100
Week 12 20 100
Week 16 20 100
Week 20 20 100
Week 24 20 100
Number %
Nausea/dyspepsia 1 0
Sedation 1 0
Dry mouth 0 7
Constipation 0 13
Insomnia 4 13
Anxiety 2 20
Tremor  3 7
Asthenia 0 0
Headache 3 13
No side effects 6 40J Clin Med Res  •  page no. to be assigned           Treatment of Burning Mouth Syndrome
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sights into the psychopathological mechanisms of BMS and 
establishment of differential diagnostic criteria are needed 
in order to develop drugs with improved efficacy and safety 
profiles for the treatment of BMS [8-10].
This study showed that amisulpride is efficacious in the 
treatment of BMS, according to the mean reduction in VAS, 
DAM-D, and HAM-A scores. With regard to the qualitative 
evaluation of clinical response, the percentage of responders 
was high. No significant differences were found between de-
mographic and clinical variables. Moreover, the demograph-
ic and clinical features of our sample were similar to those 
of other studies, except with regard to sex; in our study, all 
patients were female [11-13].
Regarding  treatment  duration,  analysis  of  the  studies 
showed that a long-term treatment (over months) was not 
necessarily more effective [1, 14]. However, we believe that 
investigation of the long-term duration of treatment is im-
portant in order to generate more reliable results in terms of 
both clinical outcomes and the possible adverse effects that 
may occur during the course of extended treatment. Many 
of the studies reviewed did not follow-up the patient [15]. In 
this respect, adequate follow-up is needed to guarantee the 
efficacy of amisulpride therapy.
Three limitations of the study need to be noted. First, 
this study was performed on an open-label basis and with-
out placebo control. It should be noted that placebo response 
rates of up to 50% have been reported in previous studies, 
and only a double-blind, placebo-controlled randomized trial 
can determine the true therapeutic profile of amisulpride in 
the treatment of BMS. Second, whether treatment response 
is similar in male patients was not determined. Third, the 
efficacy and tolerability of amisulpride have been tested in 
short-term observations, but they also need to be investigat-
ed in long-term observations.
Conclusion
Amisulpride is efficacious and well tolerated in the short-
term treatment of BMS. It is associated with good compli-
ance in the first week of treatment and short response la-
tency, and is especially useful at the beginning BMS therapy. 
However, further studies of this potentially important con-
dition are needed and the potential benefits of amisulpride 
should be confirmed under placebo-controlled conditions. In 
this sense, it would be interesting to homogenize criteria for 
expressing the results obtained.
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